We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00331175
Recruitment Status : Completed
First Posted : May 29, 2006
Last Update Posted : December 15, 2006
Information provided by:

Brief Summary:
The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.

Condition or disease Intervention/treatment Phase
Obesity Drug: Peptide YY3-36 Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Placebo- And Positive Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Doses Of Intravenous Peptide YY3-36 In Otherwise Healthy Overweight Adult Subjects
Study Start Date : July 2006
Estimated Study Completion Date : December 2006

Primary Outcome Measures :
  1. Food intake

Secondary Outcome Measures :
  1. Plasma biomarkers, safety, toleration

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI 27-35 kg/m2

Exclusion Criteria:

  • Women of childbearing potential

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00331175

United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
ClinicalTrials.gov Identifier: NCT00331175     History of Changes
Other Study ID Numbers: A9001292
First Posted: May 29, 2006    Key Record Dates
Last Update Posted: December 15, 2006
Last Verified: December 2006

Additional relevant MeSH terms:
Body Weight
Signs and Symptoms